THE EPIVAX THERAPEUTICS TEAM

Management Committee

Headshot.jpg

DAN ADAMS, JD

Chairman, EpiVax Therapeutics

Daniel Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Previously, Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion.

ADG - Headshot.jpg

ANNE (ANNIE) DE GROOT, MD

Co-Founder, CEO & CSO @ EpiVax

Annie is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She is a physician, immunologist, and co-founder and CEO/CSO of the immunoinformatics company, EpiVax.

Headshot.jpg

WILLIAM MARTIN, BA

Co-Founder, CTO & COO @ EpiVax

Bill is the principal architect and developer of the current EpiMatrix System. Over the past 19 years, Mr. Martin has revised and expanded the EpiMatrix toolkit building on the research initially performed in Dr. De Groot's Brown University laboratory.

 

Senior Technical Team

gary-d-steinberg-square headshot.jpg

GARY STEINBERG, MD

Consulting Chief Medical Officer

Gary Steinberg, MD, specializes in urologic oncology. He has been instrumental in developing innovative surgical procedures for patients with bladder cancers. In addition, Dr. Steinberg’s research includes developing new treatments for urologic cancers, especially bladder cancer. He has performed over 2500 radical cystectomies and is a national leader in continent urinary tract reconstruction. He has been a national principal investigator, scientific advisor and protocol development advisor for multiple innovative clinical trials and translational research studies utilizing novel agents including oncolytic vaccines and immunotherapeutic agents. He has been a key advisor in clinical trial design, protocol development, study completion and analysis for patients with high risk non-muscle invasive bladder cancer.

MICHAEL PRINCIOTTA, PHD

Chief Scientific Officer

Michael Princiotta brings over 20 years experience in T cell immunology and antigen processing and presentation to Epivax Therapeutics. Most recently, he was Vice President of Research at Advaxis Immunotherapies where, as head of research, he oversaw the development of a personalized cancer vaccine from conception to Phase I clinical trial. Michael holds a Master of Science in Microbiology and Molecular Biology from the University of Central Florida and a PhD in Microbiology and Immunology from the University of Colorado Health Science Center in Denver, Colorado.

EO_Michael Princiotta Headshot.jpg
M7_06364.jpg

GUILHEM RICHARD, PHD

Lead Computational Immunologist

Guilhem Richard brings immunoinformatics expertise to the EpiVax Therapeutics team. He has been a Computational Immunologist for over 4 years at EpiVax, focusing on refining its immuno-oncology platform. He holds a Master of Engineering in Bioinformatics and Modeling from the National Institute of Applied Science (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.

 

Board of Directors

Headshot.jpg
ADG - Headshot.jpg
Headshot.jpg

DAN ADAMS, JD

Chairman, EpiVax Therapeutics

Daniel Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Previously, Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion.

ANNE (ANNIE) DE GROOT, MD

Co-Founder, CEO & CSO @ EpiVax

Annie is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She is a physician, immunologist, and co-founder and CEO/CSO of the immunoinformatics company, EpiVax.

WILLIAM MARTIN, BA

Co-Founder, CTO & COO @ EpiVax

Bill is the principal architect and developer of the current EpiMatrix System. Over the past 19 years, Mr. Martin has revised and expanded the EpiMatrix toolkit building on the research initially performed in Dr. De Groot's Brown University laboratory.

RL headshot.png

RICHARD LIPKIN, MBA

Managing Director @ Easton Capital

Richard Lipkin is a Managing Director of Easton. Previously, he was a partner of Commerce Health Ventures, a life sciences healthcare fund, and Laird & Co., a private merchant bank; a biotech analyst consultant for a Goldman Sachs hedge fund and for DARPA.